News & events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
OncoArendi Therapeutics wins the award of the Stock Exchange “Company of the Year” competition 2018
14 March 2019
Clinical trials of the OATD-01 molecule will enter the next phase
11 January 2019
Submission of the application for the approval to initiate Phase 1b clinical trial for OATD-01
31 October 2018